Latanoprost 0.005% and anterior segment uveitis.
OBJECTIVE
To evaluate the association of latanoprost with anterior chamber uveitis in glaucoma patients.


METHODS
We retrospectively reviewed 527 charts in latanoprost treated patients with: no prior uveitis (Group 1); prior uveitis but were inactive at the time of the study (Group 2); and active uveitis (Group 3).


RESULTS
In Group 1 five (1.0%) of 505 patients developed uveitis after beginning latanoprost. The uveitis was trace to 1+ cell in severity and delayed in onset 99.8+/-73.9 days In Group 2 three of 13 (23.1%) patients developed delayed uveitis (trace to 1+ cell). In Group 3 zero of nine (0%) patients had worsened inflammation and the intraocular pressure remained unchanged (22.8+/-7.8 mmHg to 22.0+/-7.3 mmHg) after beginning latanoprost (p=0.38).


CONCLUSIONS
In patients without a prior history a mild delayed uveitis with latanoprost treatment may develop rarely. In patients with a uveitis history, a mild delayed exacerbation potentially may occur and the intraocular pressure may not be decreased in active uveitis.
Smith
S L
SL
Lehmann Eye Center, Nacogdoches, Texas, USA.
Pruitt
C A
CA
Sine
C S
CS
Hudgins
A C
AC
Stewart
W C
WC
D000368:Aged; D000869:Anterior Eye Segment / Q000187:drug effects* / Q000473:pathology; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy; D006801:Humans; D015994:Incidence; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D009798:Ocular Hypertension / Q000188:drug therapy; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000009:adverse effects*; D012189:Retrospective Studies; D013781:Texas / Q000453:epidemiology; D014606:Uveitis, Anterior / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology
D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost